The Liver Cancer Program regularly publishes in peer-reviewed journals on the early detection, diagnosis, prognosis, treatment, natural history and health disparities of liver cancer. You can find our papers on each topic below.
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis.Hsu CL, Wang L, Maestri E, Jacob AR, Do WL, Mayo S, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS Jr, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Stärkel P, Bataller R, Investigators A, Wang XW, Schnabl B.Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001046. PMID: 39325984
Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Do WL, Wang L, Forgues M, Liu J, Rabibhadana S, Pupacdi B, Zhao Y, Gholian H, Bhudhisawasdi V, Pairojkul C, Sukeepaisarnjaroen W, Pugkhem A, Luvira V, Lertprasertsuke N, Chotirosniramit A, Auewarakul CU, Ungtrakul T, Sricharunrat T, Sangrajrang S, Phornphutkul K, Budhu A, Harris CC, Mahidol C, Ruchirawat M, Wang XW. Cell Rep Med. 2023 Dec 19;4(12):101328. doi: 10.1016/j.xcrm.2023.101328.PMID: 38118412
A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma.
Liu J, Tang W, Budhu A, Forgues M, Hernandez MO, Candia J, Kim Y, Bowman ED, Ambs S, Zhao Y, Tran B, Wu X, Koh C, Surana P, Liang TJ, Guarnera M, Mann D, Rajaure M, Greten TF, Wang Z, Yu H, Wang XW.
Cell. 182(2):317-328, 2020.
Identification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma.Kajornsrichon W, Chaisaingmongkol J, Pomyen Y, Tit-Oon P, Wang XW, Ruchirawat M, Fuangthong M.Sci Rep. 2024 Aug 28;14(1):20012. doi: 10.1038/s41598-024-70595-0.PMID: 39198554
Liquid biopsy epigenomic profiling for cancer subtyping.Baca SC, Seo JH, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, Lakshminarayanan G, Diossy M, Qiu X, El Zarif T, Savignano H, Canniff J, Madueke I, Saliby RM, Zhang Z, Li R, Jiang Y, Taing L, Awad M, Chau CH, DeCaprio JA, Figg WD, Greten TF, Hata AN, Hodi FS, Hughes ME, Ligon KL, Lin N, Ng K, Oser MG, Meador C, Parsons HA, Pomerantz MM, Rajan A, Ritz J, Thakuria M, Tolaney SM, Wen PY, Long H, Berchuck JE, Szallasi Z, Choueiri TK, Freedman ML.Nat Med. 2023 Nov;29(11):2737-2741. doi: 10.1038/s41591-023-02605-z. Epub 2023 Oct 21.PMID: 37865722
MYC determines lineage commitment in KRAS-driven primary liver cancer development.D'Artista L, Moschopoulou AA, Barozzi I, Craig AJ, Seehawer M, Herrmann L, Minnich M, Kang TW, Rist E, Henning M, Klotz S, Heinzmann F, Harbig J, Sipos B, Longerich T, Eilers M, Dauch D, Zuber J, Wang XW, Zender L.J Hepatol. 2023 Jul;79(1):141-149. doi: 10.1016/j.jhep.2023.02.039. Epub 2023 Mar 9.PMID: 36906109
A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma.Chang CW, Chen YS, Huang CH, Lin CH, Ng WV, Chu LJ, Trépo E, Zucman-Rossi J, Siao K, Maher JJ, Chiew MY, Chou CH, Huang HD, Teo WH, Lee IS, Lo JF, Wang XW. Hepatology. 2023 Oct 23:10.1097/HEP.0000000000000637. doi: 10.1097/HEP.0000000000000637. .PMID: 37870291
Electromagnetic Tracking and Optical Molecular Imaging Guidance for Liver Biopsy and Point-of-Care Tissue Assessment in Phantom and Woodchuck Hepatocellular Carcinoma.
de Ruiter QMB, Xu S, Li M, Pritchard WF, Starost MF, Filie A, Mikhail AS, Mauda-Havakuk M, Esparza-Trujillo JA, Bakhutashvili I, Heidari P, Mahmood U, Karanian JW, Wood BJ. Cardiovascular Interventional Radiology. 2021 May 21. doi: 10.1007/s00270-021-02853-x. PMID: 34021380
Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis.
Zhu K, Tang Y, Xu X, Dang H, Tang LY, Wang X, Wang XW, Zhang YE. PLoS Biol. Dec 19;16(12): e3000091, 2018.
Mechanisms of hepatic stellate cell activation. Tsuchida T, Friedman SL. Nat Rev Gastroenterol Hepatol. Jul;14(7):397-411, 2017.
Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. Zhang Q, Matsuura K, Kleiner DE, Zamboni F, Alter HJ, Farci P. J Transl Med. Nov 28;14(1):328, 2016.
Prognostic implication and immunotherapy response prediction of a novel ubiquitination-related gene signature in liver cancer.Pan RG, Zhou J, Wang XW, Cen XK, Zhou YP, Guo YY, Feng XF.Aging (Albany NY). 2024 Jun 12;16(11):10142-10164. doi: 10.18632/aging.205926. Epub 2024 Jun 12.PMID: 38870259
Characterization of tumor evolution by functional clonality and phylogenetics in hepatocellular carcinoma. Kacar Z, Slud E, Levy D, Candia J, Budhu A, Forgues M, Wu X, Raziuddin A, Tran B, Shetty J, Pomyen Y, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Bhudhisawasdi V, Lertprasertsuke N, Auewarakul C, Sangrajrang S, Mahidol C, Ruchirawat M, Wang XW. Commun Biol. 2024 Mar 29;7(1):383. doi: 10.1038/s42003-024-06040-9.PMID: 38553628
Deep whole-genome analysis of 494 hepatocellular carcinomas. Chen L, Zhang C, Xue R, Liu M, Bai J, Bao J, Wang Y, Jiang N, Li Z, Wang W, Wang R, Zheng B, Yang A, Hu J, Liu K, Shen S, Zhang Y, Bai M, Wang Y, Zhu Y, Yang S, Gao Q, Gu J, Gao D, Wang XW, Nakagawa H, Zhang N, Wu L, Rozen SG, Bai F, Wang H. Nature. 2024 Mar;627(8004):586-593. doi: 10.1038/s41586-024-07054-3. Epub 2024 Feb 14.PMID: 38355797
Single-Cell Characterization of the Tumor Ecosystem in Liver Cancer. Wang L, Revsine M, Wang XW, Ma L.Methods Mol Biol. 2024;2769:153-166. doi: 10.1007/978-1-0716-3694-7_12.PMID: 38315396
Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing.Craig AJ, Silveira MAD, Ma L, Revsine M, Wang L, Heinrich S, Rae Z, Ruchinskas A, Dadkhah K, Do W, Behrens S, Mehrabadi FR, Dominguez DA, Forgues M, Budhu A, Chaisaingmongkol J, Hernandez JM, Davis JL, Tran B, Marquardt JU, Ruchirawat M, Kelly M, Greten TF, Wang XW. Cell Rep. 2023 Nov 28;42(11):113446. doi: 10.1016/j.celrep.2023.113446. Epub 2023 Nov 18.PMID: 37980571
Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma.Maestri E, Kedei N, Khatib S, Forgues M, Ylaya K, Hewitt SM, Wang L, Chaisaingmongkol J, Ruchirawat M, Ma L, Wang XW.Hepatology. 2024 Apr 1;79(4):768-779. doi: 10.1097/HEP.0000000000000600. Epub 2023 Sep 19.PMID: 37725716
PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma. Keggenhoff FL, Castven D, Becker D, Stojkovic S, Castven J, Zimpel C, Straub BK, Gerber T, Langer H, Hähnel P, Kindler T, Fahrer J, O'Rourke CJ, Ehmer U, Saborowski A, Ma L, Wang XW, Gaiser T, Matter MS, Sina C, Derer S, Lee JS, Roessler S, Kaina B, Andersen JB, Galle PR, Marquardt JU.Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237. Online ahead of print.PMID: 38857989
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudhari S, Kriga Y, Ylaya K, Warner AC, Edmondson EF, Forgues M, Greten TF, Wang XW. Cell Rep Med. 2023 Jun 20;4(6):101052. doi: 10.1016/j.xcrm.2023.101052. Epub 2023 May 23. PMID: 37224815; PMCID: PMC10313915.
Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma via m6A-mediated epitranscriptomic regulation. Hung MH, Chang CW, Wang KC, Chaisaingmongkol J, Ruchirawat M, Greten TF, Wang XW. Hepatology. 2023 Apr 26. doi: 10.1097/HEP.0000000000000420. PMID: 37094826.
Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Pomyen Y, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Sripan D, Chornkrathok C, Budhu A, Budhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Ungtrakul T, Sricharunrat T, Phornphutkul K, Sangrajang S, Loffredo CA, Harris CC, Mahidol C, Wang XW, Ruchirawat M; TIGER-LC Consortium. Sci Rep. 2023 Jul 14;13(1):11406. doi: 10.1038/s41598-023-38307-2. PMID: 37452065; PMCID: PMC10349051.
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M, Kelly M, Hewitt SM, Saif A, Hernandez JM, Mabry D, Kloeckner R, Greten TF, Chaisaingmongkol J, Ruchirawat M, Marquardt JU, Wang XW. Nat Commun. 2022 Dec 7;13(1):7533. doi: 10.1038/s41467-022-35291-5. PMID: 36476645; PMCID: PMC9729309.
Single-cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in HCC.
Khatib SA, Ma L, Dang H, Forgues M, Chung JY, Ylaya K, Hewitt SM, Chaisaingmongkol J, Rucchirawat M, Wang XW.
Hepatology. 2022 Sep;76(3):599-611. doi: 10.1002/hep.32345. Epub 2022 Feb 10.PMID: 35034369
Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin alphavbeta6 upregulation following liver injury. Guillot A, Guerri L, Feng D, Kim SJ, Ahmed YA, Paloczi J, He Y, Schuebel K, Dai S, Liu F, Pacher P, Kisseleva T, Qin X, Goldman D, Tacke F, Gao B. J Clin Invest. 2021 May 3;131(9):e132305. doi: 10.1172/JCI132305
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Ma L, Wang L, Khatib SA, Chang CW, Heinrich S, Dominguez DA, Forgues M, Candia J, Hernandez MO, Kelly M, Zhao Y, Tran B, Hernandez JM, Davis JL, Kleiner DE, Wood BJ, Greten TF, Wang XW. J Hepatol. 2021 Jun 30:S0168-8278(21)01848-1. doi: 10.1016/j.jhep.2021.06.028.
Understanding the Cause and Consequence of Tumor Heterogeneity. Khatib, S, Yotsawat, P, Hien, D, Wang XW. Trends in Cancer. Apr;6(4) 267-271, 2020.
Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, Kleiner DE, Hewitt SM, Ylaya K, Wood BJ, Greten TF, Wang XW. Cancer Cell. Oct 14;36(4):418-430, 2019.
MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. He, Y., Hwang, S., Cai, Y., Kim, S., Xu, M., Yang, D., Guillot, A., Feng, D., Seo, W., Gao, B. Hepatology 2019, 70:1150-1167
ALDH2 deficiency promotes alcohol-associated liver cancer by transferring harmful DNA via exosomes and activating oncogenic pathways. Seo, W., Gao, Y., He, Y., Sun, J., Xu, H., Feng, D., Park, S., Cho, Y., Guillot, A., Ren, T., Wu, R., Wang, J., Kim, S., Hwang, S., Liangpunsakul, S., Yang, Y., Niu, J., Gao, B. Journal of Hepatology 2019, 71:1000-1011.
Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.
Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, Wang XW. Hepatology. Jul;68(1):127-140, 2018.
Hepatic Hippo signaling inhibits pro-tumoral microenvironment to suppress hepatocellular carcinoma.
Kim, W., Khan, S. K., Liu, Y., Xu, R., Park, O., Cha, B., Gao, B., Yang, Y. Gut 2018, 67(9):1692-1703
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW. TIGER-LC Consortium. Cancer Cell. Jul 0;32(1):57-70.e3, 2017.
Hippo signaling interactions with Wnt/b-catenin and Notch signaling repress liver tumorigenesis.
Kim, W., Khan S., Gvozdenovic-Jeremic, J., Kim, Y., Dahlman1, J., Kim, H., Park, P., Ishitani, T., Jho, E., Gao, B., Yang, Y. Journal of Clinical Investigation 2017;127:137-152
Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. Chen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, Vera RE, Almada LL, Miamen AG, Chaiteerakij R, Zhou M, Asiedu MK, Moser CD, Han S, Hu C, Banini BA, Oseini AM, Chen Y, Fang Y, Yang D, Shaleh HM, Wang S, Wu D, Song T, Lee JS, Thorgeirsson SS, Chevet E, Shah VH, Fernandez-Zapico ME, Roberts LR.
Cancer Res. Feb 1;77(3):632-645, 2017.
DNAJB1-PRKACA fusion kinase interacts with b-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, Chen CC, Requena D, Tian S, Bosbach B, Wilkinson JE, Simon SM, Lowe SW.
Proc. Natl. Acad. Sci. U.S.A. 114: 13076-13084, 2017.
Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States.
Yang B, Shebl FM, Sternberg LR, Warner AC, Kleiner DE, Edelman DC, Gomez A, Dagnall CL, Hicks BD, Altekruse SF, Hernandez BY, Lynch CF, Meltzer PS, McGlynn KA. PLoS One. Nov 23;11(11):e0166828, 2016.
A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Iavarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, Friedman SL. Gut. Oct;65(10):1754-64, 2016.
Liver kinase B1 regulates hepatocellular tight junction distribution and function in vivo. Porat-Shliom N, Tietgens AJ, Van Itallie CM, Vitale-Cross L, Jarnik M, Harding OJ, Anderson JM, Gutkind JS, Weigert R, Arias IM.
Hepatology. Oct;64(4):1317-29, 2016.
p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW. Cell. Jul 31;158(3):579-92, 2014. Erratum in: Cell. Jun 2;165(6):1546-154, 2016.
The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.
Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM. Clinical Cancer Research. Jan 15;15(2):660-7, 2009.
The Gut Microbiome Controls Liver Tumors via the Vagus Nerve.Bauer KC, Trehan R, Ruf B, Myojin Y, Benmebarek MR, Ma C, Seifert M, Nur A, Qi J, Huang P, Soliman M, Green BL, Wabitsch S, Springer DA, Rodriguez-Matos FJ, Ghabra S, Gregory SN, Matta J, Dawson B, Golino J, Xie C, Dzutsev A, Trinchieri G, Korangy F, Greten TF.bioRxiv [Preprint]. 2024 Jan 25:2024.01.23.576951. doi: 10.1101/2024.01.23.576951.PMID: 38328040
Lineage and ecology define liver tumor evolution in response to treatment. Revsine M, Wang L, Forgues M, Behrens S, Craig AJ, Liu M, Tran B, Kelly M, Budhu A, Monge C, Xie C, Hernandez JM, Greten TF, Wang XW, Ma L. Cell Rep Med. 2024 Feb 20;5(2):101394. doi: 10.1016/j.xcrm.2024.101394. Epub 2024 Jan 26.PMID: 38280378
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma. Monge C, Xie C, Myojin Y, Coffman-D'Annibale KL, Hrones D, Brar G, Wang S, Budhu A, Figg WD, Cam M, Finney R, Levy EB, Kleiner DE, Steinberg SM, Wang XW, Redd B, Wood BJ, Greten TF.Cancer Med. 2024 Feb;13(3):e6912. doi: 10.1002/cam4.6912. Epub 2024 Jan 11.PMID: 38205877
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial. Coffman-D'Annibale K, Myojin Y, Monge C, Xie C, Hrones DM, Wood BJ, Levy EB, Kleiner D, Figg WD, Steinberg SM, Redd B, Greten TF. J Immunother Cancer. 2024 Jan 6;12(1):e008079. doi: 10.1136/jitc-2023-008079.PMID: 38184304
Innate-like T cells in liver disease. Yang AY, Wistuba-Hamprecht K, Greten TF, Ruf B.Trends Immunol. 2024 Jun 14:S1471-4906(24)00122-4. doi: 10.1016/j.it.2024.05.008. Online ahead of print.PMID: 38879436
Immunosuppressive CD29+ Treg accumulation in the liver in mice on checkpoint inhibitor therapy. Green BL, Myojin Y, Ma C, Ruf B, Ma L, Zhang Q, Rosato U, Qi J, Revsine M, Wabitsch S, Bauer K, Benmebarek MR, McCallen J, Nur A, Wang X, Sehra V, Gupta R, Claassen M, Wang XW, Korangy F, Greten TF.Gut. 2024 Feb 23;73(3):509-520. doi: 10.1136/gutjnl-2023-330024.PMID: 37770128
The Gut Microbiome Controls Liver Tumors via the Vagus Nerve. Bauer KC, Trehan R, Ruf B, Myojin Y, Benmebarek MR, Ma C, Seifert M, Nur A, Qi J, Huang P, Soliman M, Green BL, Wabitsch S, Springer DA, Rodriguez-Matos FJ, Ghabra S, Gregory SN, Matta J, Dawson B, Golino J, Xie C, Dzutsev A, Trinchieri G, Korangy F, Greten TF. 2024 Jan 25:2024.01.23.576951. doi: 10.1101/2024.01.23.576951.PMID: 38328040
Targeting WNT/β-Catenin via Modulating EZH2 Function: A New Chapter in the Treatment of β-Catenin Mutant Hepatocellular Carcinoma? Hung MH, Wang XW.Cancer Res. 2023 Nov 1;83(21):3498-3500. doi: 10.1158/0008-5472.CAN-23-2921.PMID: 37747420
Biomarkers for immunotherapy of hepatocellular carcinoma. Greten TF, Villanueva A, Korangy F, Ruf B, Yarchoan M, Ma L, Ruppin E, Wang XW.Nat Rev Clin Oncol. 2023 Nov;20(11):780-798. doi: 10.1038/s41571-023-00816-4. Epub 2023 Sep 19.PMID: 37726418 Review.
CSF-1R+ Macrophages Control the Gut Microbiome-Enhanced Liver Invariant NKT Function through IL-18. Ma C, McCallen J, McVey JC, Trehan R, Bauer K, Zhang Q, Ruf B, Wang S, Lai CW, Trinchieri G, Berzofsky JA, Korangy F, Greten TF.J Immunol. 2023 Oct 1;211(7):1099-1107. doi: 10.4049/jimmunol.2200854.PMID: 37624046
Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Ruf B, Bruhns M, Babaei S, Kedei N, Ma L, Revsine M, Benmebarek MR, Ma C, Heinrich B, Subramanyam V, Qi J, Wabitsch S, Green BL, Bauer KC, Myojin Y, Greten LT, McCallen JD, Huang P, Trehan R, Wang X, Nur A, Murphy Soika DQ, Pouzolles M, Evans CN, Chari R, Kleiner DE, Telford W, Dadkhah K, Ruchinskas A, Stovroff MK, Kang J, Oza K, Ruchirawat M, Kroemer A, Wang XW, Claassen M, Korangy F, Greten TF.Cell. 2023 Aug 17;186(17):3686-3705.e32. doi: 10.1016/j.cell.2023.07.026.PMID: 37595566
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL.Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):487-503. doi: 10.1038/s41575-023-00754-7. Epub 2023 Mar 17.PMID: 36932227 Review.
Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers. Myojin Y, McCallen JD, Ma C, Bauer KC, Ruf B, Benmebarek MR, Green BL, Wabitsch S, McVey JC, Fu C, Xie C, Greten TF. JHEP Rep. 2023 Nov 3;6(1):100959. doi: 10.1016/j.jhepr.2023.100959. eCollection 2024 Jan.PMID: 38192537
Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.
Budhu, A., Pehrsson, E.C., He, A., Goyal, L., Kelley, R.K., Dang, H., Xie, C., Monge, C., Tandon, M., Ma, L., Revsine, M., Kuhlman, L., Zhang, K., Baiev, I., Lamm, R., Patel, K., Kleiner, D.E., Hewitt, S.M., Tran, B., Shetty, J., Wu, X., Zhao, Y., Shen, T-W., Choudhari, S., Kriga, Y., Ylaya, K., Warner, A.C., Edmondson, E.F., Forgues, M., Greten, T.F., and Wang, X.W.
Cell Reports Medicine, May 23, 2023. DOI:https://doi.org/10.1016/j.xcrm.2023.101052
The Current Landscape of Therapies for Hepatocellular Carcinoma. Carcinogenesis. Coffman-D'Annibale K, Xie C, Hrones DM, Ghabra S, Greten TF, Monge C. 2023 Jul 10:bgad052. doi: 10.1093/carcin/bgad052. Epub ahead of print. PMID: 37428789.
Medication effects on the gut microbiome in allo-HCT. Robinson W, Gertz EM, Greten TF, Ruppin E. Cell. 2023 Jun 8;186(12):2520-2523. doi: 10.1016/j.cell.2023.04.011. Epub 2023 Jun 8. PMID: 37295398.
The Microbiome and Liver Cancer. Myojin Y, Greten TF. Cancer J. 2023 Mar-Apr 01;29(2):57-60. doi: 10.1097/PPO.0000000000000646. PMID: 36957974; PMCID: PMC10168020.
A gut response: Modulating chemotherapy efficacy with microbial metabolites. Bauer KC, Greten TF. Immunity. 2023 Apr 11;56(4):750-752. doi: 10.1016/j.immuni.2023.03.011. PMID: 37044066.
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. Monge C, Xie C, Myojin Y, Coffman K, Hrones DM, Wang S, Hernandez JM, Wood BJ, Levy EB, Juburi I, Hewitt SM, Kleiner DE, Steinberg SM, Figg WD, Redd B, Homan P, Cam M, Ruf B, Duffy AG, Greten TF. J Immunother Cancer. 2023 Feb;11(2):e005640. doi: 10.1136/jitc-2022-005640. PMID: 36754451; PMCID: PMC9923269.
Top advances of the year: Hepatobiliary cancers. Coffman-D'Annibale KL, Greten TF. Cancer. 2023 Apr 15;129(8):1149-1155. doi: 10.1002/cncr.34652. Epub 2023 Jan 24. PMID: 36692965.
'Invisible' immune checkpoint molecule causing resistance to anti-PD1 therapy in HCC. Greten TF.Gut. 2023 Aug;72(8):1440-1441. doi: 10.1136/gutjnl-2022-329099. Epub 2023 Jan 10.PMID: 36627186
Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity.
Ruf B, Greten TF, Korangy F. Nat Rev Cancer. 2023 Apr 20. doi: 10.1038/s41568-023-00562-w. PMID: 37081117
MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, Pan H, Wang XW, He Y, Gao B. Gut. 2023 Jan 2:gutjnl-2022-327924. doi: 10.1136/gutjnl-2022-327924. Epub ahead of print. PMID: 36593103.
Immunology and immunotherapy of cholangiocarcinoma. Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW.
Nat Rev Gastroenterol Hepatol. 2023 Jan 25. doi: 10.1038/s41575-022-00741-4. PMID: 36697706
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. J Immunother Cancer. 2022 Sep;10(9):e005413. doi: 10.1136/jitc-2022-005413. PMID: 36175037; PMCID: PMC9528604.
Interventional radiology meets immuno-oncology for hepatocellular carcinoma. Salem R, Greten TF. J Hepatol. 2022 Aug 19:S0168-8278(22)03003-3. doi: 10.1016/j.jhep.2022.08.003. PMID: 35988688.
Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Heinrich B, Ruf B, Subramanyam V, Myojin Y, Lai CW, Craig AJ, Fu J, Xie C, Kroemer A, Greten TF, Korangy F. Front Immunol. 2022 Jun 27;13:849958. doi: 10.3389/fimmu.2022.849958. PMID: ; PMCID: PMC9271772.
IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, White KF, Masia R, Titerina EK, Fatkhullina AR, Cousineau I, Turcotte S, Zhigarev D, Marchenko A, Khoziainova S, Makhov P, Tan YF, Kossenkov AV, Wiest DL, Stagg J, Wang XW, Campbell KS, Dzutsev AK, Trinchieri G, Hill JA, Grivennikov SI, Koltsova EK. Cancer Discov. 2022 Aug 5;12(8):1960-1983. doi: 10.1158/2159-8290.CD-20-1628. PMID: 35723626; PMCID: PMC9357073.
Creatine riboside is a cancer cell-derived metabolite associated with arginine auxotrophy. Parker AL, Toulabi L, Oike T, Kanke Y, Patel D, Tada T, Taylor S, Beck JA, Bowman E, Reyzer ML, Butcher D, Kuhn S, Pauly GT, Krausz KW, Gonzalez FJ, Hussain SP, Ambs S, Ryan BM, Wang XW, Harris CC. J Clin Invest. 2022 Jul 15;132(14):e157410. doi: 10.1172/JCI157410. PMID: 35838048; PMCID: PMC9282934.
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, Ruf B, Brown Z, Heinrich B, Zhang Q, Rosato U, Wang S, Cui L, Berzofsky JA, Kleiner DE, Bosco DB, Wu LJ, Lai CW, Rotman Y, Xie C, Korangy F, Greten TF.
Cancer Cell. 2022 Sep 12;40(9):986-998.e5. doi: 10.1016/j.ccell.2022.08.004. Epub 2022 Sep 1.PMID: 36055226
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M, Kelly M, Hewitt SM, Saif A, Hernandez JM, Mabry D, Kloeckner R, Greten TF, Chaisaingmongkol J, Ruchirawat M, Marquardt JU, Wang XW. Nat Commun 13, 7533 (2022). https://doi.org/10.1038/s41467-022-35291-5
Intestinal MYC modulates obesity-related metabolic dysfunction. Luo Y, Yang S, Wu X, Takahashi S, Sun L, Cai J, Krausz KW, Guo X, Dias HB, Gavrilova O, Xie C, Jiang C, Liu W, Gonzalez FJ. Nature Metabolism. 2021 Jul;3(7):923-939. doi: 10.1038/s42255-021-00421-8. Epub 2021 Jul 1.PMID: 34211180
Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. Mauda-Havakuk M, Mikhail AS, Starost MF, Jones EC, Karim B, Kleiner DE, Partanen A, Esparza-Trujillo JA, Bakhutashvili I, Wakim PG, Kassin MT, Lewis AL, Karanian JW, Wood BJ, Pritchard WF. Journal of Hepatocellular Carcinoma. 2021 Mar 9;8:71-83. doi: 10.2147/JHC.S287800. PMID: 33728278; PMCID: PMC7955744.
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. Luo Y, Gao Y, Liu W, Yang Y, Jiang J, Wang Y, Tang W, Yang S, Sun L, Cai J, Guo X, Takahashi S, Krausz KW, Qu A, Chen L, Xie C, Gonzalez FJ. Hepatology. 2021 Apr 25. doi: 10.1002/hep.31864. Online ahead of print.PMID: 33896016
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui LL, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Kroemer A, Wang XW, Ruchirawat M, Korangy F, Schnabl B, Trinchieri G, Greten TF. Cancer Discovery. 2021 May;11(5):1248-1267. doi: 10.1158/2159-8290.CD-20-0304. Epub 2020 Dec 15.PMID: 33323397
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP, Ruf B, Ma C, Heinrich B, Cui L, Zhang Q, McVey JC, Wabitsch S, Heinrich S, Rosato U, Lai W, Subramanyam V, Longerich T, Loosen SH, Luedde T, Neumann UP, Desar S, Kleiner D, Gores G, Wang XW, Greten TF. J Hepatology. 2021 May;74(5):1145-1154. doi: 10.1016/j.jhep.2020.11.037. Epub 2020 Dec 1.PMID: 33276030
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
Heinrich S, Craig AJ, Ma L, Heinrich B, Greten TF, Wang XW. J Hepatology. 2021 Mar;74(3):700-715. doi: 10.1016/j.jhep.2020.11.036. Epub 2020 Nov 30.PMID: 33271159
Drug-eluting embolic microspheres: State-of-the-art and emerging clinical applications. Mikhail AS, Negussie AH, Mauda-Havakuk M, Owen JW, Pritchard WF, Lewis AL, Wood BJ. Expert Opinion Drug Delivery 2021 Jan 22:1-16. Doi: 10.1080/17425247.2021.1835858. Online ahead of print. PMID: 33480306
Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization. Negussie AH, de Ruiter QMB, Britton H, Donahue DR, Boffi Q, Kim YS, Pritchard WF, Moonen C, Storm G, Lewis AL, Wood BJ.
Scientific Reports. 2021 Jan 12;11(1):533. doi: 10.1038/s41598-020-79900-z. PMID: 33436734
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Fleming BD, Urban DJ, Hall MD, Longerich T, Greten TF, Pastan I, Ho M.
Hepatology. 2020 May;71(5):1696-1711. doi: 10.1002/hep.30949. Epub 2020 Jan 27.PMID: 31520528 Free PMC article.
Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Li D, Li N, Zhang Y-F, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, Kramer J, Duan Z, Yang H, Kolluri A, Hummer AM, Torres MB, Zhu H, Hall MD, Luo X, Chen J, Wang Q, Abate-Daga D, Dropublic B, Hewitt SM, Orentas RJ, Greten TF, Ho M. Gastroenterology. Jun;158(8):2250-2265, 2020.
Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Fu Y, Urban DJ, Nani RR, Zhang YF, Li N, Fu H, Shah H, Gorka AP, Guha R, Chen L, Hall MD, Schnermann MJ, Ho M.
Hepatology. 2019 Aug;70(2):563-576. doi: 10.1002/hep.30326. Epub 2019 Feb 19.PMID: 30353932 Free PMC article.
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF.
Science. May 25;360(6391), 2018.
ONC201 kills breast cancer cells in vitro by targeting mitochondria. Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S.
Oncotarget. Apr 6;9(26):18454-18479, 2018.
Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model. Escorcia FE, Steckler JM, Abdel-Atti D, Price EW, Carlin SD, Scholz WW, Lewis JS, Houghton JL. Mol Imaging Biol. Mar 5; [Epub ahead of print], 2018.
An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Shuptrine CW, Ajina R, Fertig EJ, Jablonski SA, Kim Lyerly H, Hartman ZC, Weiner LM.
Cancer Immunol Immunother. Dec;66(12):1529-1544, 2017.
Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression.
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, Greten TF. Cancer Cell. Oct 10;30(4):533-547, 2016.
First Human Experience with Directly Image-able Iodinated Embolization Microbeads.
Levy EB, Krishnasamy VP, Lewis AL, Willis S, Macfarlane C, Anderson V, van der Bom IM, Radaelli A, Dreher MR, Sharma KV, Negussie A, Mikhail AS, Geschwind JF, Wood BJ. Cardiovascular Interventional Radiology. 2016 Aug;39(8):1177-86 PMID: 27206503
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L. Nature Medicine. Jul;22(7):744-53, 2016.
Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis.
Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M. Nature Communications. Mar 11; 6:6536, 2015.
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. Cancer Immunol Res. Dec;2(12):1186-98, 2014.
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Proc Natl Acad Sci U S A. Mar 19;110(12):E1083-91, 2013.
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L. Nature. Nov 9;479(7374):547-51, 2011.
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, Benezra R, Scheinberg DA. Cancer Research. Nov 15;70(22):9277-86, 2010.
Unveiling Disparities: Analyzing Hispanic Inclusion in Liver Cancer Research Databases in the United States.Figueroa GA, Greten TF, Bonilla CM.J Racial Ethn Health Disparities. 2024 Sep 23. doi: 10.1007/s40615-024-02178-8. Online ahead of print.PMID: 39312090
Aldehydes alter TGF-β signaling and induce obesity and cancer. Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur RL, Hassan MI, Mohammad T, Crandall K, Cifani P, Shetty K, Lyons SK, Merrill JR, Vegesna AK, John S, Latham PS, Crawford JM, Mishra B, Dasarathy S, Wang XW, Yu H, Wang Z, Huang H, Krainer AR, Mishra L.Cell Rep. 2024 Sep 24;43(9):114676. doi: 10.1016/j.celrep.2024.114676. Epub 2024 Aug 31.PMID: 39217614
Hispanic Individuals are Underrepresented in Phase III Clinical Trials for Advanced Liver Cancer in the United States. Monge C, Maldonado JA, McGlynn KA, Greten TF.J Hepatocell Carcinoma. 2023 Jul 27;10:1223-1235. doi: 10.2147/JHC.S412446. eCollection 2023.PMID: 37533601
Dissecting liver tumor heterogeneity to improve health equity Ma, L and Wang, XW. Trends in Cancer. 2022, Apr;8(4):286-290.
Immunologic Markers and Risk of Hepatocellular Carcinoma in HBV- and HCV-infected Individuals.
Koshiol J, Argirion I, Liu Z, Lam T, O'Brien TR, Yu K, McGlynn KA, Petrick JL, Pinto L, Hildesheim A, Pfeiffer R, Lee M, Yang HI.
Alimentary Pharmacology & Therapeutics 2021;54(6):833-842. Epub 2021/07/19. doi: 10.1111/apt.16524.
Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes. Nepal C, Zhu B, O'Rourke CJ (co-first authors), Bhatt DK, Lee D, Song L, Wang D, Van Dyke A, Choo-Wosoba H, Liu Z, Hildesheim A, Goldstein AM, Dean M, LaFuente-Barquero J, Lawrence S, Mutreja K, Olanich ME, Bermejo JL, Group CGRES, Ferreccio C, Roa JC, Rashid A, Hsing AW, Gao YT, Chanock SJ, Araya JC, Andersen JB, Koshiol J (co-last authors).
Journal of Hepatology. 2021;74(5):1132-1144. Epub 2020/12/05. doi: 10.1016/j.jhep.2020.11.033.
Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. Jackson SS, Adami HO, Andreotti G, Beane-Freeman LE, de Gonzalez AB, Buring JE, Fraser GE, Freedman ND, Gapstur SM, Gierach G, Giles GG, Grodstein F, Hartge P, Jenab M, Kirsh V, Knutsen SF, Lan Q, Larsson SC, Lee IM, Lee MH, Liao LM, Milne RL, Monroe KR, Neuhouser ML, O'Brien KM, Petrick JL, Purdue MP, Rohan TE, Sandin S, Sandler DP, Sawada N, Shadyab AH, Simon TG, Sinha R, Stolzenberg-Solomon R, Tsugane S, Weiderpass E, Wolk A, Yang HI, Zheng W, McGlynn KA, Campbell PT, Koshiol J.
Journal of Hepatology. 2020;73(4):863-72. Epub 2020/05/22. doi: 10.1016/j.jhep.2020.04.046.
Association Between Aspirin Use and Biliary Tract Cancer Survival. Jackson SS, Pfeiffer RM, Liu Z, Anderson LA, Tsai HT, Gadalla SM, Koshiol J. JAMA Oncology. 2019. Epub 2019/10/18. doi: 10.1001/jamaoncol.2019.4328.
Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Liu Z, Alsaggaf R, McGlynn KA, Anderson LA, Tsai HT, Zhu B, Zhu Y, Mbulaiteye SM, Gadalla SM, Koshiol J. Gut. 2019;68(8):1458-64. Epub 2018/11/19. doi: 10.1136/gutjnl-2018-317504.
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW. TIGER-LC Consortium.
Cancer Cell. Jul 0;32(1):57-70.e3, 2017.
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cancer Genome Atlas Research Network.
Cell. Jun 15;169(7):1327-1341.e23, 2017.